Glioma-associated protein CHI3L2 suppresses cells viability and induces G1/S transition arrest
Aim. To analyze the effect of the CHI3L2 protein on malignant and non-malignant cell viability, and determined the CHI3L2 impact on the cell cycle and signaling pathways involved in the cell cycle regulation. Methods. MTT-based cell proliferation assay, FACS, western blot analysis. Results. The CHI3...
Saved in:
Date: | 2015 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Published: |
Інститут молекулярної біології і генетики НАН України
2015
|
Series: | Вiopolymers and Cell |
Subjects: | |
Online Access: | http://dspace.nbuv.gov.ua/handle/123456789/152612 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Journal Title: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
Cite this: | Glioma-associated protein CHI3L2 suppresses cells viability and induces G1/S transition arrest / S.S. Avdieiev, L. Gera, R. Hodges, V.V. Dmytrenko // Вiopolymers and Cell. — 2015. — Т. 31, № 4. — С. 316-320. — Бібліогр.: 8 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of UkraineSummary: | Aim. To analyze the effect of the CHI3L2 protein on malignant and non-malignant cell viability, and determined the CHI3L2 impact on the cell cycle and signaling pathways involved in the cell cycle regulation. Methods. MTT-based cell proliferation assay, FACS, western blot analysis. Results. The CHI3L2 protein inhibits the glioma cells viability and potentiates the effect of anti-cancer cytotoxic agents. The CHI3L2 treatment results in the G1/S transition arrest. CHI3L2 provoked a dramatic reduction of pRB phosphorylation and a significant decrease in the cyclin D1 expression, whereas the p53 and p21 expression levels were substantially increased. Conclusions. The CHI3L2 protein, which is overexpressed in human gliomas, is a negative regulator of the glioma cells viability. The reduced cell viability after the CHI3L2 treatment could be due to the activation of pRB and p53 and the downregulation of cyclin D. |
---|